Our top pick for
Amedisys, Inc is a medical care facilities business based in the US. Amedisys shares (AMED) are listed on the NASDAQ and all prices are listed in US Dollars. Amedisys employs 21,000 staff and has a trailing 12-month revenue of around USD$2 billion.
|52-week range||USD$132.9495 - USD$325.12|
|50-day moving average||USD$297.8444|
|200-day moving average||USD$260.848|
|Wall St. target price||USD$320.54|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$4.992|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Amedisys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amedisys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amedisys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Amedisys shares trade at around 56x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Amedisys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0852. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amedisys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amedisys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$230.5 million.
The EBITDA is a measure of a Amedisys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2 billion|
|Operating margin TTM||10.12%|
|Gross profit TTM||USD$805.3 million|
|Return on assets TTM||9.08%|
|Return on equity TTM||24.62%|
|Market capitalisation||USD$9.2 billion|
TTM: trailing 12 months
There are currently 397,879 Amedisys shares held short by investors – that's known as Amedisys's "short interest". This figure is 12.9% down from 456,769 last month.
There are a few different ways that this level of interest in shorting Amedisys shares can be evaluated.
Amedisys's "short interest ratio" (SIR) is the quantity of Amedisys shares currently shorted divided by the average quantity of Amedisys shares traded daily (recently around 180035.74660633). Amedisys's SIR currently stands at 2.21. In other words for every 100,000 Amedisys shares traded daily on the market, roughly 2210 shares are currently held short.
However Amedisys's short interest can also be evaluated against the total number of Amedisys shares, or, against the total number of tradable Amedisys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amedisys's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Amedisys shares in existence, roughly 10 shares are currently held short) or 0.0141% of the tradable shares (for every 100,000 tradable Amedisys shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amedisys.
Find out more about how you can short Amedisys stock.
We're not expecting Amedisys to pay a dividend over the next 12 months.
Amedisys's shares were split on a 4:3 basis on 5 December 2006. So if you had owned 3 shares the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Amedisys shares – just the quantity. However, indirectly, the new 25% lower share price could have impacted the market appetite for Amedisys shares which in turn could have impacted Amedisys's share price.
Over the last 12 months, Amedisys's shares have ranged in value from as little as $132.9495 up to $325.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amedisys's is 0.7284. This would suggest that Amedisys's shares are less volatile than average (for this exchange).
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.